Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3532226 in obesity
NCT06557356Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of macupatide in obesity (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment Emergent Adverse Events at 16 weeks. Started Aug 2024; status: completed.
02
Drugs
macupatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06557356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557356.